StockData
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc. (AVBP) stock

AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$10.69−0.87 (-7.53%)

Close on Nov 17, 2026Market cap $527.10MP/E –Yield –

ArriVent BioPharma cash

Cash and short-term investments held at the end of each period.

ArriVent BioPharma's cash was $373.12M at Jun 30, 2026. For fiscal 2025 it was $312.82M, up 42.9% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$312.82M+42.9%
FY2024Dec 31, 2024$218.86M+45.5%
FY2023Dec 31, 2023$150.39M-7.9%
FY2022Dec 31, 2022$163.37M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$373.12M+58.3%
Q1 FY2026Mar 31, 2026$326.38M+85.4%
Q4 FY2025Dec 31, 2025$312.82M+42.9%
Q3 FY2025Sep 30, 2025$300.27M+6.2%
Q2 FY2025Jun 30, 2025$235.69M-21.1%
Q1 FY2025Mar 31, 2025$176.08M-44.5%
Q4 FY2024Dec 31, 2024$218.86M+45.5%
Q3 FY2024Sep 30, 2024$282.86M+100.1%
Q2 FY2024Jun 30, 2024$298.67M+89.2%
Q1 FY2024Mar 31, 2024$317.39M+65.8%
Q4 FY2023Dec 31, 2023$150.39M-7.9%
Q3 FY2023Sep 30, 2023$141.36M–
Q2 FY2023Jun 30, 2023$157.83M–
Q1 FY2023Mar 31, 2023$191.46M–
Q4 FY2022Dec 31, 2022$163.37M–

More ArriVent BioPharma figures

See a number that looks wrong?